CBDM.T®, The Market and Business Intelligence Company Reviews The
According to CBDMT®, the market and business intelligence company, contract
biomanufacturing is a significant market estimated at €2.3 billion this year with an annual
growth of about 10 to 15%. Pharmaceutical biomanufacturing could account for more than 20%
of the global contract manufacturing market in 2012.
Paris, France (PRWEB) September 15, 2008 -- Biologics are products derived from living organisms or their
products. The manufacturing of such biologics involves the culture or manufacturing of living organisms and is
named biomanufacturing. According to CBDM.T, biologic drugs (including vaccines), corresponding to less than
12% of global sales in 2001, are expected to contribute 30% of the global drug sales in 2012. Growing
pharmaceutical market categories such as vaccines, HIV, neurodegeneration, anti-inflammation, cancer and
diabetes reflect continued penetration of biologics. By being derived from living organisms, biologics are
complex molecules that are difficult to manufacture. Compared to small molecules, this is a tremendous
"advantage" making the development of generic version extremely difficult.
Manufacturing of biologics or biomanufacturing is a multi-step process with a current 60:40 split between
mammalian cell culture and microbial fermentation. Today about 60% of all recombinant protein pharmaceuticals
are produced in mammalian cells (Avastin, Advate, Erbitux, Rebif, Herceptin, Advate, Fabrazyme…) and 40%
are produced in microbial cells (E.coli: Infergen, Ontak, Enbrel and yeast: Novolog, Twinrix Pediarix…).
Microbial fermentation is used when smaller and less complex molecules with no post-translational modifications
are required (peptides, small proteins, enzymes and antibody fragment). Mammalian cell culture is definitely
dominating the manufacturing of complex proteins (glycosylated) and monoclonal antibodies. Transgenics, plant
systems or microalgae are still at development stage and could